Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Cost of Revenue: 2023-2025

Historic Cost of Revenue for Immunocore Holdings (IMCR) over the last 3 years, with Sep 2025 value amounting to $513,000.

  • Immunocore Holdings' Cost of Revenue rose 14.51% to $513,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 4.34%. This contributed to the annual value of $2.7 million for FY2024, which is 163.36% up from last year.
  • Immunocore Holdings' Cost of Revenue amounted to $513,000 in Q3 2025, which was down 50.67% from $1.0 million recorded in Q2 2025.
  • Immunocore Holdings' Cost of Revenue's 5-year high stood at $1.7 million during Q2 2024, with a 5-year trough of $200,000 in Q4 2023.
  • Its 3-year average for Cost of Revenue is $559,364, with a median of $346,000 in 2023.
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 393.35% in 2024, then tumbled by 39.07% in 2025.
  • Immunocore Holdings' Cost of Revenue (Quarterly) stood at $200,000 in 2023, then spiked by 65.00% to $330,000 in 2024, then grew by 14.51% to $513,000 in 2025.
  • Its last three reported values are $513,000 in Q3 2025, $1.0 million for Q2 2025, and $831,000 during Q1 2025.